News | December 24, 2023
Bristol Myers Squibb to buy Karuna Therapeutics for US$ 14 billion
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Evinova will operate as a separate health-tech business within AstraZeneca
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
The collaboration brings a seamless digital experience to more formulators worldwide
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
The World Homoeopathy Day commemorates the birth anniversary of Dr Samuel Hahnemann on 10th of April
His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Subscribe To Our Newsletter & Stay Updated
